<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485912</url>
  </required_header>
  <id_info>
    <org_study_id>EBL06</org_study_id>
    <nct_id>NCT02485912</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination</brief_title>
  <official_title>A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire le Dantec (CHUD), Dakar, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial in which healthy volunteers will be administered two experimental
      Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z. Two groups of volunteers will be vaccinated with
      both vaccines one after the other in a prime/boost regimen.

      All ChAd3-EBO Z doses are 2.5 x 10^10 - 3.7 x 10^10 vp and all MVA-EBO Z doses are 1.0 x 10^8
      pfu.

      All volunteers will receive a ChAd3-EBO Z priming vaccine and a MVA-EBO Z boosting vaccine 7
      days later.

      The site of administration of the MVA-EBO Z vaccine differs between the two groups:

      Group 1 will receive the MVA-EBO Z vaccine in the same arm as the ChAd3-EBO Z vaccine.

      Group 2 will receive the MVA-EBO Z vaccine in the opposite arm from the ChAd3-EBO Z vaccine.

      The study will assess the safety of the vaccinations, and the immune responses to
      vaccination. Immune responses are measured by tests on blood samples.

      The ChAd3-EBO Z and MVA-EBO Z vaccines are called viral vectored vaccines. They are made from
      viruses which are modified so that they cannot multiply. The viruses have extra DNA in them
      so that after injection, the body makes Ebola proteins (but Ebola does not develop), so that
      the immune system builds a response to Ebola without having been infected by it.

      Healthy volunteers will be recruited in Dakar, Senegal. The study will be funded by GSK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CHUD study team will hold sensitisation meetings, in specific areas targeting specific
      populations, to explain the study to potential volunteers. During these meetings the
      investigators will explain the following: the need for a vaccine (including a simple picture
      of the burden of the Ebola disease and how it affects the community); the current status of
      vaccine development (including the fact that this is likely to be a prolonged process that
      probably will not influence the course of the current epidemic); the study screening and
      informed consent procedure; risks of vaccination and the unproven benefits of this
      vaccination. It will be stressed that this is an experimental vaccine and there is no current
      evidence that it will provide protection, and that it will therefore still be necessary to
      take preventive measures and to seek treatment if ill for any reason after vaccination.

      After these sensitisation meetings, the CT team will actively identify. The study will be
      further explained to eligible participants on individual basis. Potential volunteers will be
      invited to the CHUD CT site for further discussion. Potential volunteers will be informed
      that they are free to withdraw from the CT at any time without giving any reason. Individuals
      who feel that the trial is appropriate for them will be invited to attend a formal screening
      visit.

      Detailed information about the study will be provided in a Participant Information Sheet
      (PIS) at least 24 hours prior to the consent being undertaken. The informed consent process
      will start before the screening visit. The volunteer will be given the opportunity to ask
      about details of the trial, and will then have time to consider whether or not to
      participate. The investigators will ensure that the volunteers are briefed on the contents of
      the PIS in the language they understand. The investigators will also ensure that all
      volunteers fully understand the risks. Any volunteer who appears to have less than complete
      understanding will not be enrolled.

      All volunteers will sign and date the informed consent form before any study specific
      procedures (including screening visit) are performed. If the volunteer is illiterate, s/he
      will sign the informed consent form; in the latter case a literate adult impartial witness
      will be present throughout the whole consenting process, write subject's name and date of
      signature and will sign and date the consent form. Volunteers will sign and date two copies
      of the consent form, one for them to take away and keep, and one to be stored in the
      subject's medical records.

      Vaccinations in Group 1 can commence 7 days after vaccination after interim safety review of
      the first 5 volunteers receiving the same dose in the UK CT. The first 5 volunteers will be
      vaccinated in a staggered fashion.

      The first volunteer to receive the ChAd63-EBO Z vaccine dose in Group 1 will be vaccinated
      alone and we will wait 24 hours before vaccinating subsequent volunteers in this group. Two
      further Group 1 volunteers will be vaccinated 24 hours after the first, and then at least
      another 24 hours gap will pass before vaccinating further subjects receiving the ChAd63-EBO Z
      vaccine in Groups 1 &amp; 2.

      The same staggered vaccine administration procedure will be adopted for vaccinations with the
      MVA-EBO Z vaccine. A total of 20 volunteers will be enrolled in this group.

      In Group 2, vaccination can commence after 5 volunteers in Groups 1 have received the
      ChAd63-EBO Z vaccine dose. The same staggered vaccine administration procedure as for Group 1
      will be adopted for vaccinations with the MVA-EBO Z vaccine. A total of 20 volunteers will be
      enrolled in this group.

      Volunteers will be visited daily at home by a study field worker or nurse to record adverse
      events (solicited and unsolicited for six consecutive days after vaccination). Additional
      scheduled visits at the CHUD clinic will be at day 7, 14, 28, 35, 56, 90, 180 post-first
      vaccination during which interim history will be collected, physical examination and blood
      tests performed at the time-points indicated in the schedule of attendances. Blood will also
      be taken for exploratory immunology analysis.

      All volunteers will be followed up for 6 months beginning from the day of the first
      vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of administration of ChAd3-EBO Z and MVA-EBO Z 7 days later. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAd3-EBO Z</intervention_name>
    <description>This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-EBO Z</intervention_name>
    <description>This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18 to 50 years

          -  Able and willing (in the Investigator's opinion) to comply with all study requirements

          -  For females only, willingness to practice continuous effective contraception (see
             section 6.4.3) during the study and a negative pregnancy test on the day(s) of
             screening and vaccination

          -  Agreement to refrain from blood donation during the course of the study

          -  Provide written informed consent

        Exclusion Criteria:

          -  Participation in another research study involving receipt of an investigational
             product in the 30 days preceding enrolment, or planned participation during the study
             period

          -  Prior receipt of an investigational Ebola or Marburg vaccine, a chimpanzee adenovirus
             vectored vaccine, an MVA vaccine or any other investigational vaccine likely to impact
             on interpretation of the trial data

          -  Receipt of any live, attenuated vaccine within 28 days prior to enrolment

          -  Receipt of any subunit or killed vaccine within 14 days prior to enrolment

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the planned administration of the vaccine candidate

          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)
             immunosuppressant medication within the past 6 months (inhaled and topical steroids
             are allowed)

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine, (e.g. egg products) including urticaria, respiratory difficulty or
             abdominal pain

          -  Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.

          -  Any history of anaphylaxis in reaction to vaccination

          -  Pregnancy, lactation or willingness/intention to become pregnant during the study

          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in
             situ)

          -  History of current or previous psychiatric illness.

          -  Poorly controlled asthma or thyroid disease

          -  Seizure in the past 3 years or treatment for seizure disorder in the past 3 years

          -  Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior
             history of significant bleeding or bruising following IM injections or venepuncture

          -  Any other serious chronic illness

          -  Current anti-tuberculosis prophylaxis or therapy

          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater
             than 42 units every week

          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment

          -  Seropositive for hepatitis B surface antigen (HBsAg)

          -  History of contact with suspected, probable or confirmed cases of Ebola in the
             previous 21 days

          -  Any clinically significant abnormal finding on screening biochemistry or haematology
             blood tests or urinalysis (see Appendix A &amp; B)

          -  Any other significant disease, disorder or finding which may significantly increase
             the risk to the volunteer because of participation in the study, affect the ability of
             the volunteer to participate in the study or impair interpretation of the study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Souleymane Mboup, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire le Dantec (CHUD), Dakar, Senegal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire le Dantec</name>
      <address>
        <city>Dakar</city>
        <zip>BP 7325</zip>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Dixon MG, Schafer IJ; Centers for Disease Control and Prevention (CDC). Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):548-51.</citation>
    <PMID>24964881</PMID>
  </reference>
  <reference>
    <citation>Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2013 Jan;158(1):301-11. doi: 10.1007/s00705-012-1454-0. Epub 2012 Sep 23.</citation>
    <PMID>23001720</PMID>
  </reference>
  <reference>
    <citation>Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993 Sep;29(3):215-40.</citation>
    <PMID>8237108</PMID>
  </reference>
  <reference>
    <citation>Sanchez A, Kiley MP, Klenk HD, Feldmann H. Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol. 1992 Feb;73 ( Pt 2):347-57.</citation>
    <PMID>1538192</PMID>
  </reference>
  <reference>
    <citation>Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol. 2003 May;33(5-6):583-95. Review.</citation>
    <PMID>12782057</PMID>
  </reference>
  <reference>
    <citation>Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004 Dec;10(12 Suppl):S110-21. Review.</citation>
    <PMID>15577929</PMID>
  </reference>
  <reference>
    <citation>Meslin FX. Global aspects of emerging and potential zoonoses: a WHO perspective. Emerg Infect Dis. 1997 Apr-Jun;3(2):223-8.</citation>
    <PMID>9204308</PMID>
  </reference>
  <reference>
    <citation>Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, Rwaguma EB, Kagwa P, Lamunu M. An outbreak of Ebola in Uganda. Trop Med Int Health. 2002 Dec;7(12):1068-75.</citation>
    <PMID>12460399</PMID>
  </reference>
  <reference>
    <citation>Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med. 2005 Dec;5(8):761-72. Review.</citation>
    <PMID>16375711</PMID>
  </reference>
  <reference>
    <citation>Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol. 2003 Sep;77(18):9733-7. Review.</citation>
    <PMID>12941881</PMID>
  </reference>
  <reference>
    <citation>Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.</citation>
    <PMID>16988008</PMID>
  </reference>
  <reference>
    <citation>Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.</citation>
    <PMID>21034824</PMID>
  </reference>
  <reference>
    <citation>Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000 Aug;6(8):886-9.</citation>
    <PMID>10932225</PMID>
  </reference>
  <reference>
    <citation>Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006 Jun;3(6):e177. Epub 2006 May 16.</citation>
    <PMID>16683867</PMID>
  </reference>
  <reference>
    <citation>Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8802-6.</citation>
    <PMID>8090727</PMID>
  </reference>
  <reference>
    <citation>Top FH Jr, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK, Buescher EL. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis. 1971 Aug;124(2):148-54.</citation>
    <PMID>4330997</PMID>
  </reference>
  <reference>
    <citation>Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, Tesema L, Li Y, Gao GP, Xiang ZQ, Zhou D, Wilson JM, Ertl HC. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther. 2007 Mar;15(3):608-17. Epub 2007 Jan 16.</citation>
    <PMID>17228314</PMID>
  </reference>
  <reference>
    <citation>Bruña-Romero O, González-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11491-6. Epub 2001 Sep 11.</citation>
    <PMID>11553779</PMID>
  </reference>
  <reference>
    <citation>Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001 Dec;75(23):11603-13.</citation>
    <PMID>11689642</PMID>
  </reference>
  <reference>
    <citation>Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson JM, Ertl HC. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006 Mar;13(5):421-9.</citation>
    <PMID>16319951</PMID>
  </reference>
  <reference>
    <citation>Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.</citation>
    <PMID>22218690</PMID>
  </reference>
  <reference>
    <citation>O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.</citation>
    <PMID>22275401</PMID>
  </reference>
  <reference>
    <citation>Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.</citation>
    <PMID>22218691</PMID>
  </reference>
  <reference>
    <citation>Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, Cortese R, Colloca S, Ciliberto G, La Monica N, Aurisicchio L. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine. 2009 Feb 25;27(9):1293-300. doi: 10.1016/j.vaccine.2008.12.051. Epub 2009 Jan 20.</citation>
    <PMID>19162112</PMID>
  </reference>
  <reference>
    <citation>Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013 Mar 15;190(6):2720-35. doi: 10.4049/jimmunol.1202861. Epub 2013 Feb 6.</citation>
    <PMID>23390298</PMID>
  </reference>
  <reference>
    <citation>Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS; VRC 207 Study Team. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017 Mar 9;376(10):928-938. doi: 10.1056/NEJMoa1410863. Epub 2014 Nov 26.</citation>
    <PMID>25426834</PMID>
  </reference>
  <reference>
    <citation>Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.</citation>
    <PMID>25629663</PMID>
  </reference>
  <reference>
    <citation>Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90. German.</citation>
    <PMID>219640</PMID>
  </reference>
  <reference>
    <citation>Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine. 2009 Aug 6;27(36):4975-82. doi: 10.1016/j.vaccine.2009.05.083. Epub 2009 Jun 14.</citation>
    <PMID>19531390</PMID>
  </reference>
  <reference>
    <citation>Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine. 2009 Jan 29;27(5):748-56. doi: 10.1016/j.vaccine.2008.11.066. Epub 2008 Dec 9.</citation>
    <PMID>19071186</PMID>
  </reference>
  <reference>
    <citation>Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.</citation>
    <PMID>21282192</PMID>
  </reference>
  <reference>
    <citation>Howles S, Guimarães-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, McMichael A, Dorrell L. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine. 2010 Oct 21;28(45):7306-12. doi: 10.1016/j.vaccine.2010.08.077. Epub 2010 Sep 16.</citation>
    <PMID>20816902</PMID>
  </reference>
  <reference>
    <citation>Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010 Jan;40(1):279-90. doi: 10.1002/eji.200939754. Erratum in: Eur J Immunol. 2011 May;41(5):1501.</citation>
    <PMID>20017188</PMID>
  </reference>
  <reference>
    <citation>Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011 Jan 1;52(1):1-7. doi: 10.1093/cid/ciq015.</citation>
    <PMID>21148512</PMID>
  </reference>
  <reference>
    <citation>Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother. 2010 Jun;59(6):863-73. doi: 10.1007/s00262-009-0811-7. Epub 2009 Dec 31.</citation>
    <PMID>20043222</PMID>
  </reference>
  <reference>
    <citation>Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010 Jan;8(1):62-73. doi: 10.1038/nrmicro2240. Review.</citation>
    <PMID>19966816</PMID>
  </reference>
  <reference>
    <citation>Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, Molyneux C, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials. 2006 Oct 20;1(6):e29.</citation>
    <PMID>17053830</PMID>
  </reference>
  <reference>
    <citation>Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004 Nov;1(2):e33. Epub 2004 Oct 26.</citation>
    <PMID>15526058</PMID>
  </reference>
  <reference>
    <citation>Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, Laidlaw SM, Peto T, Skinner MA, Gilbert SC, Hill AV. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine. 2006 Apr 5;24(15):3026-34. Epub 2006 Feb 2.</citation>
    <PMID>16488059</PMID>
  </reference>
  <reference>
    <citation>Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.</citation>
    <PMID>22363582</PMID>
  </reference>
  <reference>
    <citation>Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011 Dec;19(12):2269-76. doi: 10.1038/mt.2011.176. Epub 2011 Aug 23.</citation>
    <PMID>21862998</PMID>
  </reference>
  <reference>
    <citation>Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.</citation>
    <PMID>23526949</PMID>
  </reference>
  <reference>
    <citation>Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.</citation>
    <PMID>23089736</PMID>
  </reference>
  <reference>
    <citation>Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.</citation>
    <PMID>24284865</PMID>
  </reference>
  <reference>
    <citation>Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011 Aug 21;17(9):1128-31. doi: 10.1038/nm.2447.</citation>
    <PMID>21857654</PMID>
  </reference>
  <reference>
    <citation>Malaeb BS, Gardner TA, Margulis V, Yang L, Gillenwater JY, Chung LW, Macik G, Koeneman KS. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. Urology. 2005 Oct;66(4):830-4.</citation>
    <PMID>16230147</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola</keyword>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

